Komori
Share Issuance and Disposal4875MediciNova,Inc.Pharmaceuticals

Notice Regarding the Establishment of an Issuance Limit for New Shares Under the U.S. Shelf Registration System and the Issuance of New Shares Thereunder

Under the U.S. shelf registration system, the Company established an ATM offering program under which it may flexibly sell up to US$50 million of its common shares. Sales will be conducted through Lucid Capital Markets, LLC as sales agent, and the proceeds are expected to be used for research and development and other purposes.

Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
50000000
US dollars
Wording
Conditional
How definitive the wording is.

Details of issuance or disposal

Issuance of new common shares through a public offering (At-The-Market (ATM) Offering)

Intended allottee
Investors in the public offering (no specific allottee stated)
Total issue value

Up to US$50 million

Amount of funds to be raised
Total amount to be paid: Not disclosed; estimated net proceeds: Not disclosed
Specific use of funds
Research and development related to MN-166 and MN-001, and general corporate purposes
Offering structure
Underwriter / lead underwriter
Lucid Capital Markets, LLC (sales agent and broker-dealer)
Payment date
The business day following the sale date
Basis for determining the amount to be paid
Determined based on the market price of the Company's common shares on the Nasdaq Global Market at the time of sale, a price based on the market price, or another lawful method
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of new common shares through a public offering (At-The-Market (ATM) Offering)
Issue price and disposal priceThe market price of the Company's common shares on the Nasdaq Global Market at the time of sale, a price based on the market price, or a price determined by another lawful method
Total issue valueUp to US$50 million
Amount of funds to be raisedTotal amount to be paid: Not disclosed; estimated net proceeds: Not disclosed
Specific use of fundsDetails Research and development related to MN-166 and MN-001, and general corporate purposes / Amount Not disclosed / Scheduled timing of expenditures Not disclosed
Payment dateThe business day following the sale date
Intended allotteeInvestors in the public offering (no specific allottee stated)
Basis for determining the amount to be paidDetermined based on the market price of the Company's common shares on the Nasdaq Global Market at the time of sale, a price based on the market price, or another lawful method
Underwriter / lead underwriterLucid Capital Markets, LLC (sales agent and broker-dealer)
Items this document does not state (19)
Number of shares to be issued or disposed ofEstimated issuance expensesIntended allottee's holding policyDilution RateTotal number of issued sharesExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To fund research and development related to MN-166 and MN-001 and for general corporate purposes. The funds will also enable the Company to raise capital flexibly in the United States and Japan.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Establishment of an Issuance Limit for New Shares Under the U.S. Shelf Registration System and the Issuance of New Shares Thereunder | MediciNova,Inc. (4875) timely disclosure | Komori